Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1828459rdf:typepubmed:Citationlld:pubmed
pubmed-article:1828459lifeskim:mentionsumls-concept:C0027481lld:lifeskim
pubmed-article:1828459lifeskim:mentionsumls-concept:C0079284lld:lifeskim
pubmed-article:1828459lifeskim:mentionsumls-concept:C0005823lld:lifeskim
pubmed-article:1828459lifeskim:mentionsumls-concept:C0018935lld:lifeskim
pubmed-article:1828459lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1828459lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:1828459pubmed:issue6 Pt 2lld:pubmed
pubmed-article:1828459pubmed:dateCreated1991-7-12lld:pubmed
pubmed-article:1828459pubmed:abstractTextInfusion of endothelin has been observed to increase hematocrit, and the peptide also stimulates release of atrial natriuretic peptide (ANP) both in vitro and in vivo. We studied the relation of these two actions of endothelin in anesthetized, bilaterally nephrectomized Sprague-Dawley rats. Infusion of endothelin (25 ng/kg/min) for 45 minutes produced a modest increase in blood pressure of 12% from a baseline of 99 +/- 5 mm Hg and an increase in hematocrit of 8.0 +/- 0.6%, reflecting a reduction in plasma volume of 13.1 +/- 0.9%. These changes each exceeded greatly those observed after 45 minutes of vehicle infusion. Plasma protein concentration, however, increased only by 4.2 +/- 0.6%, suggesting protein extravasation, which was confirmed by finding an endothelin-dependent increase in the accumulation of Evans blue dye in heart, skeletal muscle, and intestine, but not liver, lung, brain, or testis. Endothelin infusion increased plasma immunoreactive ANP concentration from 196 +/- 50 to 722 +/- 203 pg/ml (p less than 0.02), and a close correlation existed between the increase in plasma immunoreactive ANP and immunoreactive endothelin concentrations as a result of the infusion (r = 0.84, p less than 0.01). Pretreatment of rats with rabbit anti-rat ANP antiserum did not affect baseline variables but led to an exaggerated increase in blood pressure (25.3 +/- 2.9%, p less than 0.002 versus endothelin alone). No change in hematocrit occurred. Thus, the increase in plasma immunoreactive ANP concentration resulting from endothelin infusion mediates the increase in hematocrit through an increase in vascular permeability to whole plasma.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1828459pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1828459pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1828459pubmed:languageenglld:pubmed
pubmed-article:1828459pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1828459pubmed:citationSubsetIMlld:pubmed
pubmed-article:1828459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1828459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1828459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1828459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1828459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1828459pubmed:statusMEDLINElld:pubmed
pubmed-article:1828459pubmed:monthJunlld:pubmed
pubmed-article:1828459pubmed:issn0194-911Xlld:pubmed
pubmed-article:1828459pubmed:authorpubmed-author:GardnerD GDGlld:pubmed
pubmed-article:1828459pubmed:authorpubmed-author:HumphreysM...lld:pubmed
pubmed-article:1828459pubmed:authorpubmed-author:WiedemannEElld:pubmed
pubmed-article:1828459pubmed:authorpubmed-author:ValentinJ PJPlld:pubmed
pubmed-article:1828459pubmed:issnTypePrintlld:pubmed
pubmed-article:1828459pubmed:volume17lld:pubmed
pubmed-article:1828459pubmed:ownerNLMlld:pubmed
pubmed-article:1828459pubmed:authorsCompleteYlld:pubmed
pubmed-article:1828459pubmed:pagination864-9lld:pubmed
pubmed-article:1828459pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:meshHeadingpubmed-meshheading:1828459-...lld:pubmed
pubmed-article:1828459pubmed:year1991lld:pubmed
pubmed-article:1828459pubmed:articleTitleModulation of endothelin effects on blood pressure and hematocrit by atrial natriuretic peptide.lld:pubmed
pubmed-article:1828459pubmed:affiliationDivision of Nephrology, San Francisco General Hospital, CA 94110.lld:pubmed
pubmed-article:1828459pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1828459pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:1828459pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1828459lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1828459lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1828459lld:pubmed